Ruminococcaceae

Ruminococcaceae relative abundance was significantly reduced in critically ill ICU patients compared to healthy controls (ANCOM-II p-adj<0.1), representing a key anaerobic fermenter family lost during critical illness-associated gut dysbiosis in a prospective cohort of 51 patients.

PMID: 36894652

D016638 Critical Illness D064806 Dysbiosis

Ruminococcaceae depletion preceded Enterobacteriaceae expansion in critically ill ICU patients, consistent with its role in colonization resistance against pathobiont expansion during critical illness-associated gut dysbiosis.

PMID: 36894652

D016638 Critical Illness D064806 Dysbiosis

In an independent newly recruited cohort of 132 anti-PD-1–treated metastatic melanoma patients (n=87 responders, n=45 non-responders), Ruminococcaceae relative abundance was significantly higher in responders versus non-responders (p=0.036 by Wilcoxon rank sum test), replicating the response-associated enrichment pattern identified in a prior cohort.

PMID: 34941392

D000082082 Immune Checkpoint Inhibitors D008545 Melanoma H00038 Melanoma

Across an expanded cohort of 293 metastatic melanoma patients treated with anti-PD-1 or other systemic therapies, Ruminococcaceae was the most significantly enriched taxon in gut microbiota of responders versus non-responders (FDR q<0.1 by Wilcoxon rank sum test), with enrichment persisting after multivariable adjustment for age, sex, BMI, prior treatment, and antibiotic use.

PMID: 34941392

D000082082 Immune Checkpoint Inhibitors D008545 Melanoma D000077982 Progression-Free Survival H00038 Melanoma

Ruminococcaceae relative abundance was significantly higher in anti-PD-1 responders versus non-responders in a prospective cohort of 43 metastatic melanoma patients (30R, 13NR; p<0.01 by LEfSe and FDR-adjusted pairwise comparisons), establishing the original human evidence for Ruminococcaceae enrichment as a gut microbiome marker of immunotherapy response.

PMID: 29097493

D000082082 Immune Checkpoint Inhibitors D008545 Melanoma H00038 Melanoma

In a phase 1 FMT trial (n=10 anti-PD-1-refractory metastatic melanoma patients), FMT Donor 2 (a melanoma complete responder) was characterized by high Ruminococcaceae relative abundance in stool microbiota; the paper explicitly characterizes this as a previously reported 'immunotherapy-favorable feature' associated with anti-PD-1 response, though Donor 2 recipients produced no clinical responses in this trial.

PMID: 33303685

D000069467 Fecal Microbiota Transplantation D000069196 Gastrointestinal Microbiome D000082082 Immune Checkpoint Inhibitors D008545 Melanoma H00038 Melanoma